Ipamorelina vs CJC-1295 (bez DAC): Sygnalizacja GHSR vs GHRH
Redakcja
Dział badań
To zlokalizowane podsumowanie przedstawia temat w ujęciu opartym na dowodach. Pełna treść pozostaje w języku angielskim dla spójności redakcyjnej.
Ipamorelin vs CJC-1295 (No DAC): GHSR vs GHRH Signaling
Ipamorelin and CJC-1295 (No DAC) are one of the most frequently discussed peptide pairs in GH-axis research because they stimulate a related endocrine outcome through different receptor pathways. Ipamorelin targets GHSR-1a (ghrelin receptor). CJC-1295 No DAC signals through pituitary GHRH receptors. This dual-entry architecture is what makes them useful for pathway-isolation studies and complementary protocols.
Side-by-Side
| Property | Ipamorelin | CJC-1295 (No DAC) |
|---|---|---|
| Primary Receptor Target | GHSR-1a | GHRH receptor |
| Compound Class | GH secretagogue peptide | GHRH analog (short-acting) |
| Typical Signal Pattern | Pulse-trigger oriented | Pulse-support oriented |
| Common Research Use | Ghrelin-pathway pulse studies | GHRH-pathway pulse studies |
| Combination Logic | Complementary with GHRH analogs | Complementary with GHSR agonists |
The DAC Question (Why "No DAC" Matters Here)
CJC-1295 exists in two forms: with DAC (drug affinity complex — a modification that binds albumin and extends half-life to several days) and without DAC (short-acting, matches natural pulsatile GHRH timing more closely). This comparison uses No DAC intentionally, because the pulse-timing logic of a stack with ipamorelin depends on a short-acting GHRH analog. See the dedicated CJC-1295 DAC vs No DAC framing for why that distinction matters.
Why This Pair Is So Common in GH-Axis Protocols
Because ipamorelin and CJC-1295 No DAC engage separate receptors within the same axis, they enable cleaner tests of pathway contribution and reduce overreliance on a single signaling node. In pulse-window experiments where temporal control drives interpretation, pairing ghrelin-receptor triggering with GHRH-pathway support produces a more physiologic signal shape.
Comparator Design: Isolate First, Stack Second
Good methodology separates ipamorelin and CJC-1295 before combining them. Isolate each compound in its own arm to characterize pulse behavior; then add a combined arm to test additive or synergistic signaling. Skipping the isolation step introduces confounds that make the stack arm hard to interpret.
Bottom Line
Ipamorelin and CJC-1295 No DAC are paired so often because their receptors are genuinely complementary — not because they are redundant. The research value is in understanding which signaling layer each compound represents, then designing protocols that respect that architecture.
Educational content only. Not medical advice.
Dowody i cytowania
Recenzowane źródła powiązane z peptidami w tym przewodniku. Ułatwia weryfikację, porównania i cytowanie.
Ipamorelin, the first selective growth hormone secretagogue
Ipamorelin • Raun K, et al. • Eur J Endocrinol (1998)
DOI: 10.1530/eje.0.1390552Sermorelin: a growth hormone-releasing hormone analog
Sermorelin • Thorner MO, et al. • J Clin Endocrinol Metab (1993)
DOI: 10.1210/jcem.77.5.8077320Modified GRF (1-29) for growth hormone release
Mod GRF 1-29 • Jetté L, et al. • J Clin Endocrinol Metab (1991)
DOI: 10.1210/jcem-72-4-857Zobacz w repozytorium
FAQ — odpowiedzi pierwsze
Krótkie pytania i odpowiedzi dla czytelności i silników odpowiedzi.
What is the difference between CJC-1295 with DAC and without DAC?
With DAC includes a drug affinity complex that binds albumin and extends half-life to several days, producing sustained GHRH-like exposure. Without DAC is short-acting and aligns more closely with natural pulsatile GHRH timing. The stack logic with ipamorelin generally assumes the No DAC form.
Is CJC-1295 the same as Mod GRF 1-29?
Mod GRF 1-29 is often used synonymously with CJC-1295 No DAC in research catalogs — both refer to a stabilized 1-29 GHRH analog without the DAC modification. Naming can vary by supplier.
Peptydy klasy badawczej z testami zewnętrznymi i certyfikatem analizy.
Shop Peptides